OBJECTIVE: To estimate the association between duration of combination antiretroviral therapy (cART) during pregnancy and low infant birthweight (LBW), among women ≥37 weeks of gestation. DESIGN: We conducted a retrospective cohort study of HIV-infected women who met eligibility criteria based on CD4 count ≤350 but had not started cART at entry into antenatal care. Our cohort was restricted to births that occurred ≥37 weeks of gestation. METHODS: We used Poisson models with robust variance estimators to estimate risk ratios (RRs) and 95% confidence intervals (CIs). RESULTS: Of 50,765 HIV-infected women with antenatal visits between January 2009 and September 2013, 4474 women met the inclusion criteria. LBW occurred in 302 pregnancies (7%). Nearly two-thirds of women (62%) eligible to initiate cART never started treatment. Overall, 14% were on cART for ≤8 weeks, 22% for 9-20 weeks, and 2% for 21-36 weeks. There was no evidence of an increased risk of LBW for women receiving cART for ≤8 weeks (RR = 1.22; 95% CI: 0.77 to 1.91), 9-20 weeks (RR = 1.23; 95% CI: 0.82 to 1.83), or 21-36 weeks (RR = 0.87; 95% CI: 0.22 to 3.46), compared with women who never initiated treatment. These findings were consistent across several sensitivity analyses. CONCLUSIONS: Longer duration of cART was not associated with poor fetal growth among term pregnancies in our cohort. However, the relationship between cART and adverse pregnancy outcomes remains complicated. Continued work is required to investigate causality. An understanding cART's impact on adverse pregnancy outcomes is essential as cART becomes the cornerstone of preventing mother-to-child transmission programs globally.
OBJECTIVE: To estimate the association between duration of combination antiretroviral therapy (cART) during pregnancy and low infant birthweight (LBW), among women ≥37 weeks of gestation. DESIGN: We conducted a retrospective cohort study of HIV-infectedwomen who met eligibility criteria based on CD4 count ≤350 but had not started cART at entry into antenatal care. Our cohort was restricted to births that occurred ≥37 weeks of gestation. METHODS: We used Poisson models with robust variance estimators to estimate risk ratios (RRs) and 95% confidence intervals (CIs). RESULTS: Of 50,765 HIV-infectedwomen with antenatal visits between January 2009 and September 2013, 4474 women met the inclusion criteria. LBW occurred in 302 pregnancies (7%). Nearly two-thirds of women (62%) eligible to initiate cART never started treatment. Overall, 14% were on cART for ≤8 weeks, 22% for 9-20 weeks, and 2% for 21-36 weeks. There was no evidence of an increased risk of LBW for women receiving cART for ≤8 weeks (RR = 1.22; 95% CI: 0.77 to 1.91), 9-20 weeks (RR = 1.23; 95% CI: 0.82 to 1.83), or 21-36 weeks (RR = 0.87; 95% CI: 0.22 to 3.46), compared with women who never initiated treatment. These findings were consistent across several sensitivity analyses. CONCLUSIONS: Longer duration of cART was not associated with poor fetal growth among term pregnancies in our cohort. However, the relationship between cART and adverse pregnancy outcomes remains complicated. Continued work is required to investigate causality. An understanding cART's impact on adverse pregnancy outcomes is essential as cART becomes the cornerstone of preventing mother-to-child transmission programs globally.
Authors: Jennifer Y Chen; Heather J Ribaudo; Sajini Souda; Natasha Parekh; Anthony Ogwu; Shahin Lockman; Kathleen Powis; Scott Dryden-Peterson; Tracy Creek; William Jimbo; Tebogo Madidimalo; Joseph Makhema; Max Essex; Roger L Shapiro Journal: J Infect Dis Date: 2012-10-12 Impact factor: 5.226
Authors: Ruth E Tuomala; David E Shapiro; Lynne M Mofenson; Yvonne Bryson; Mary Culnane; Michael D Hughes; M J O'Sullivan; Gwendolyn Scott; Alice M Stek; Diane Wara; Marc Bulterys Journal: N Engl J Med Date: 2002-06-13 Impact factor: 91.245
Authors: Eszter Papp; Hakimeh Mohammadi; Mona R Loutfy; Mark H Yudin; Kellie E Murphy; Sharon L Walmsley; Rajiv Shah; Jay MacGillivray; Michael Silverman; Lena Serghides Journal: J Infect Dis Date: 2014-07-16 Impact factor: 5.226
Authors: Angela M Bengtson; Daniel Westreich; Patrick Musonda; Audrey Pettifor; Carla Chibwesha; Benjamin H Chi; Bellington Vwalika; Brian W Pence; Jeffrey S A Stringer; William C Miller Journal: Epidemiology Date: 2016-09 Impact factor: 4.822
Authors: Maganizo B Chagomerana; William C Miller; Brian W Pence; Mina C Hosseinipour; Irving F Hoffman; Robert J Flick; Hannock Tweya; Soyapi Mumba; Frank Chimbwandira; Kimberly A Powers Journal: J Acquir Immune Defic Syndr Date: 2017-04-01 Impact factor: 3.731
Authors: Ushma C Mehta; Cari van Schalkwyk; Prineetha Naidoo; Arthi Ramkissoon; Otty Mhlongo; Niren R Maharaj; Niree Naidoo; Karen Fieggen; Michael F Urban; Shaun Krog; Alex Welte; Mukesh Dheda; Yogan Pillay; Neil F Moran Journal: South Afr J HIV Med Date: 2019-09-30 Impact factor: 2.744